TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06423014

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable devices only
Description: self-monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices only
Description: self-monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices only
Description: self-monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices only
Description: self-monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices only
Description: self-monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices only
Description: self-monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices only
Description: self-monitoring

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable devices with the 1st behavior change technique
Description: reminder

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable devices with the 2nd behavior change technique
Description: social support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable devices with the 3rd behavior change technique
Description: Competition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable devices with the 4th behavior change technique
Description: Goal-setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable devices with the 5th behavior change technique
Description: health coach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable devices with all behavior change techniques
Description: Self-monitoring, health coach, goal-setting, competition, social support, and reminder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices with all behavior change techniques
Description: Self-monitoring, health coach, goal-setting, competition, social support, and reminder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices with all behavior change techniques
Description: Self-monitoring, health coach, goal-setting, competition, social support, and reminder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices with all behavior change techniques
Description: Self-monitoring, health coach, goal-setting, competition, social support, and reminder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices with all behavior change techniques
Description: Self-monitoring, health coach, goal-setting, competition, social support, and reminder
Study: NCT06477328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Video calls were made with the telemedicine group.
Study: NCT06335147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab, mFOLFOX6
Description: Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
Study: NCT05508594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT001
Description: Intranasal
Study: NCT05554146

Intervention type: OTHER
Group type: OTHER
Intervention: Receipt of Coupon for Placebo Soft-Gel Capsule
Description: The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study

Intervention type: OTHER
Group type: OTHER
Intervention: Receipt of Coupon for High THC Soft-Gel Capsule
Description: The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study

Intervention type: OTHER
Group type: OTHER
Intervention: Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule
Description: The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study

Intervention type: OTHER
Group type: OTHER
Intervention: Receipt of Coupon for High CBD Soft-Gel Capsule
Description: The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
Study: NCT05462652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
Study: NCT06364319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD25 rhMAb
Description: 1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses. For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
Study: NCT06423014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices with all behavior change techniques
Description: Self-monitoring, health coach, goal-setting, competition, social support, and reminder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable devices with all behavior change techniques
Description: Self-monitoring, health coach, goal-setting, competition, social support, and reminder
Study: NCT06364319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Maintain pre-screening dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Maintain pre-screening dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 10mg, BID PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib
Description: 10mg, BID PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 1.25mg/kg, BID PO/IV, target:150-250ng/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine
Description: 1.25mg/kg, BID PO/IV, target:150-250ng/ml
Study: NCT06361992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue Cap Foam
Description: Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
Study: NCT05796778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subomohyoid plane block
Description: The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
Study: NCT05593601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin
Description: Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
Study: NCT06041776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib + Icotinib placebo
Description: The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).
Study: NCT05508594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal
Study: NCT06041776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib + Befotertinib placebo
Description: Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis.
Study: NCT04729946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu Cleansing Device
Description: The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
Study: NCT05508594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal
Study: NCT05080244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 2 strains 10x10\^9 UFC/capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Potato starch and magnesium stearate
Study: NCT05508594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal
Study: NCT06010875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
Study: NCT05029570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction System Pacing (pacemaker implantation)
Description: Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
Study: NCT05094440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy skills training (DBT-ST)
Description: Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical behavioral therapy skills training (DBT-ST)
Description: Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
Study: NCT05429515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFR-SUPRA
Description: HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemodialysis
Description: hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: chemotherapy protocol will be made by hematologists.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: chemotherapy protocol will be made by hematologists.
Study: NCT05914883

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Long-term continuous ECG monitoring
Description: Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
Study: NCT04951739

Intervention type: PROCEDURE
Intervention: Peroral endoscopic myotomy
Description: Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
Study: NCT06116240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed disodium for injection
Description: Pemetrexed disodium is a multi-target antifolate antineoplastic drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Cisplatin is a chemotherapy drug.
Study: NCT05125185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation
Description: To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation
Description: To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
Study: NCT05587465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lobster Device
Description: The intervention is performed percutaneously using the dedicated instrument set.
Study: NCT06581627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: 2 tablets of Etavopivat will be administered in fasted state via oral route
Study: NCT05508594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal
Study: NCT06510478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Life Skill Intervention
Description: This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
Study: NCT04806945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to HLX10
Description: IV infusion
Study: NCT05869825

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Canula following extubation
Description: Participants in this group will be randomized to receive High Flow Nasal Cannula support after extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Positive Pressure Ventilation following extubation
Description: Participants in this group will be randomized to receive NIPPV respiratory support following extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
Study: NCT04564885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAGUERA®C Cervical Disc Prosthesis
Description: surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobi-C Cervical Disc
Description: surgery
Study: NCT03932097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL Parenting
Description: REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Materials
Description: NIAAA materials on underage drinking for parents
Study: NCT06154681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: World Digital Detox Family Program
Description: The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
Study: NCT06299423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Howdy Senior® device
Description: Standard perioperative management plus three preoperative and twelve postoperative (until 90 days after surgery) HOWDY Senior® device assessments.